Single-Center Experience with Trabectedin for the Treatment of Non-L-sarcomas

Serda, P. Cerda; Terés, Raul; Sebio, Ana; Bagué, Sílvia; Orellana, Ruth; Moreno, Miquel; Riba, Mireia; López‐Pousa, Antonio

doi:10.1007/s12325-022-02051-2

Cited by 4 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therapeutic strategies targeting macrophages within the HCC microenvironment aim to induce the conversion of M2 macrophages into M1 macrophages and to counteract immune suppression. Trabectedin, a macrophage-targeted drug initially designed for the treatment of soft tissue sarcomas [ 65 ], is a marine bioactive extract known for its specific cytotoxicity against macrophages. Other potential drugs, such as the immunomodulator LineMode, act to inhibit macrophage activity in tumor angiogenesis.…”

Section: Anti-tumor Therapy Targeting Macrophagesmentioning

confidence: 99%

Targeting the macrophage immunocheckpoint: a novel insight into solid tumor immunotherapy

Zhou,

Yang,

Kang

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Tumor immunotherapy, which targets immune checkpoints, presents a promising strategy for the treatment of various cancer types. However, current clinical data indicate challenges in its application to solid tumors. Recent studies have revealed a significant correlation between the degree of immune response in immunotherapy and the tumor microenvironment, particularly with regard to tumor-infiltrating immune cells. Among these immune cells, macrophages, a critical component, are playing an increasingly vital role in tumor immunotherapy. This review focuses on elucidating the role of macrophages within solid tumors and provides an overview of the progress in immunotherapy approaches centered around modulating macrophage responses through various immune factors.

show abstract

Section: Anti-tumor Therapy Targeting Macrophagesmentioning

confidence: 99%

Targeting the macrophage immunocheckpoint: a novel insight into solid tumor immunotherapy

Zhou,

Yang,

Kang

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

show abstract

Trabectedin

2022

Reactions Weekly

View full text Add to dashboard Cite

Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis

et al. 2022

View full text Add to dashboard Cite

BackgroundAmong sarcomas, which are rare cancers with an incidence of <6 per 100.000/year cases, ultra-rare sarcomas have an incidence of approximately ≤1/1,000,000/year cases and altogether account for ~20% of all soft tissue sarcomas (STS) and bone sarcomas. The Italian Sarcoma Group has recently performed a non-interventional, retrospective TrObs study with data from 512 anthracycline-pretreated patients with advanced multiple STS histologies and treated with trabectedin (Palmerini, Cancers 2021; ClinicalTrials.gov Identifier: NCT02793050).MethodsA post-hoc analysis of case series to evaluate the efficacy and safety of trabectedin on patients with ultra-rare and other rare translocation-related sarcomas included in TrObs study was performed. Main outcomes comprised investigator-assessed overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and safety.ResultsThirty-six patients (18 women) with ultra-rare and other rare sarcoma and a median age of 53.0 years (range: 22-81) were included. Most patients had solitary fibrous tumor (SFT; n=11) followed by epithelioid sarcoma (n=5), malignant peripheral nerve sheath tumor (MPNST; n=4), extraskeletal myxoid chondrosarcoma (EMC; n=3), desmoplastic small round cell tumor (DSRCT; n=3), and alveolar soft part sarcoma (ASPS), rhabdomyosarcoma and clear cell sarcoma (n=2 each). Thirty-five patients had metastatic disease and 23 patients received trabectedin as a second-line treatment. Among 35 patients evaluable for response, two patients with SFT and ASPS had a partial response and one patient with DSRCT obtained a complete response, reaching an ORR of 8.6% (95% CI: 2.8-23.4%). Among patients with an ORR, 6-months PFS was 100% in patients with ASPS, 45.7% in patients with SFT and 33.3% in those with DSRCT. Two patients with epithelioid sarcoma and myoepithelioma had disease stabilization lasting >24 months. Nine patients had at least one grade 3/4 adverse event, mostly being bone marrow toxicity (n=6).ConclusionsTrabectedin has some anti-tumor activity in some ultra-rare and other rare sarcomas, particularly translocation-related sarcomas, with the well-known manageable safety profile.

show abstract

Single-Center Experience with Trabectedin for the Treatment of Non-L-sarcomas

Cited by 4 publications

References 27 publications

Targeting the macrophage immunocheckpoint: a novel insight into solid tumor immunotherapy

Targeting the macrophage immunocheckpoint: a novel insight into solid tumor immunotherapy

Trabectedin

Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis

Contact Info

Product

Resources

About